Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639847 | 0.81 | KDM4E (0.50) | PLA2G2AADORA1 | |
| SCHEMBL2908237 | 0.79 | HTT (0.58) | L3MBTL1PLA2G2A | |
| SCHEMBL2906933 | 0.77 | NPSR1 (0.53) | PLA2G2A | |
| SCHEMBL641038 | 0.75 | KDM4E (0.56) | PLA2G2A | |
| SCHEMBL2909757 | 0.74 | KCNN4 (0.47) | PLA2G2AKCNN4 | |
| SCHEMBL10085136 | 0.73 | KCNN4 (0.38) | PLA2G2AKCNN4ADORA1 | |
| SCHEMBL638972 | 0.73 | BRD4 (0.41) | PLA2G2AKCNN4ADORA1 | |
| SCHEMBL2907639 | 0.72 | PLA2G2A (0.44) | PLA2G2A | |
| SCHEMBL2901560 | 0.71 | NPSR1 (0.42) | PLA2G2A | |
| SCHEMBL640905 | 0.71 | PLA2G2A (0.39) | PLA2G2AKCNN4ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121627-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| US-8119675-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119675-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2121627-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2008101586-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016372-A1 | Benzimidazole Derivatives | GPR119, GLP1R, H1-3 | L3MBTL1 855/4885ASAH1 4451/4885PLA2G2A 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.